BSE Live
Dec 19, 16:01Prev. Close
1279.60
Open Price
1272.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 19, 15:55Prev. Close
1280.00
Open Price
1277.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1278.20 (345)
| Key Financial Ratios of Dr Reddys Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 50.12 | 33.30 | 28.17 | 69.60 | 27.53 | |
| Diluted EPS (Rs.) | 50.12 | 33.30 | 28.17 | 69.60 | 27.53 | |
| Cash EPS (Rs.) | 64.44 | 45.97 | 39.03 | 78.63 | 43.78 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 350.39 | 312.30 | 286.12 | 260.45 | 294.95 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 350.39 | 312.30 | 286.12 | 260.45 | 294.95 | |
| Dividend / Share(Rs.) | 11.25 | 6.25 | 3.75 | 3.75 | 5.00 | |
| Revenue from Operations/Share (Rs.) | 260.40 | 237.50 | 198.84 | 225.31 | 261.20 | |
| PBDIT/Share (Rs.) | 77.68 | 55.70 | 44.75 | 91.19 | 51.20 | |
| PBIT/Share (Rs.) | 64.51 | 44.20 | 35.12 | 83.24 | 36.68 | |
| PBT/Share (Rs.) | 64.27 | 43.32 | 34.73 | 81.34 | 34.39 | |
| Net Profit/Share (Rs.) | 50.12 | 33.30 | 28.17 | 69.60 | 27.53 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 29.83 | 23.45 | 22.50 | 40.47 | 19.60 | |
| PBIT Margin (%) | 24.77 | 18.61 | 17.66 | 36.94 | 14.04 | |
| PBT Margin (%) | 24.67 | 18.23 | 17.46 | 36.10 | 13.16 | |
| Net Profit Margin (%) | 19.24 | 14.02 | 14.16 | 30.89 | 10.53 | |
| Return on Networth / Equity (%) | 14.30 | 10.66 | 9.84 | 26.72 | 9.33 | |
| Return on Capital Employed (%) | 14.05 | 10.42 | 9.61 | 26.22 | 9.01 | |
| Return on Assets (%) | 10.11 | 7.62 | 7.11 | 19.61 | 5.29 | |
| Total Debt/Equity (X) | 0.10 | 0.12 | 0.10 | 0.08 | 0.41 | |
| Asset Turnover Ratio (%) | 52.57 | 54.35 | 50.19 | 63.49 | 50.27 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.55 | 1.95 | 1.92 | 2.67 | 1.45 | |
| Quick Ratio (X) | 1.16 | 1.57 | 1.55 | 2.35 | 1.18 | |
| Inventory Turnover Ratio (X) | 4.90 | 5.44 | 5.22 | 7.76 | 4.52 | |
| Dividend Payout Ratio (NP) (%) | 22.45 | 18.77 | 13.31 | 5.38 | 18.16 | |
| Dividend Payout Ratio (CP) (%) | 17.46 | 13.60 | 9.60 | 4.76 | 11.42 | |
| Earnings Retention Ratio (%) | 77.55 | 81.23 | 86.69 | 94.62 | 81.84 | |
| Cash Earnings Retention Ratio (%) | 82.54 | 86.40 | 90.40 | 95.24 | 88.58 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 21,747.58 | 8,484.77 | 9,863.15 | 11,088.80 | 11,165.86 | |
| EV/Net Operating Revenue (X) | 4.95 | 2.12 | 2.95 | 2.93 | 5.57 | |
| EV/EBITDA (X) | 16.58 | 9.05 | 13.11 | 7.24 | 28.44 | |
| MarketCap/Net Operating Revenue (X) | 4.90 | 2.06 | 2.97 | 3.23 | 5.44 | |
| Retention Ratios (%) | 77.54 | 81.22 | 86.68 | 94.61 | 81.83 | |
| Price/BV (X) | 3.64 | 1.56 | 2.07 | 2.79 | 4.82 | |
| Price/Net Operating Revenue | 4.90 | 2.06 | 2.97 | 3.23 | 5.44 | |
| Earnings Yield | 0.04 | 0.07 | 0.05 | 0.10 | 0.02 |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz